HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kristen Hege Selected Research

idecabtagene vicleucel

11/2023Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
1/2023Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.
1/2022Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial.
1/2022Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.
10/2021Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
1/2021Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
1/2019Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kristen Hege Research Topics

Disease

17Neoplasms (Cancer)
03/2022 - 02/2004
12Multiple Myeloma
11/2023 - 10/2015
5Prostatic Neoplasms (Prostate Cancer)
01/2019 - 07/2007
3Non-Hodgkin Lymphoma (Lymphosarcoma)
09/2020 - 04/2015
2Thrombocytopenia (Thrombopenia)
03/2022 - 01/2019
2Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
02/2022 - 04/2015
2Disease Progression
01/2020 - 10/2015
2Lymphoma (Lymphomas)
01/2020 - 04/2015
2Glioblastoma (Glioblastoma Multiforme)
01/2019 - 10/2013
1Cytokine Release Syndrome
11/2023
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
03/2022
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
03/2022
1Diarrhea
03/2022
1Febrile Neutropenia
03/2022
1Monosomy
01/2021
1Hyperglycemia
01/2019
1Squamous Cell Carcinoma of Head and Neck
01/2019
1Asthenia
01/2019
1Carcinoid Tumor (Carcinoid)
01/2019
1Fatigue
01/2019
1Nausea
01/2019
1Ewing Sarcoma (Sarcoma, Ewing)
01/2019
1Stomatitis
01/2019
1Neuroendocrine Tumors (Neuroendocrine Tumor)
01/2019
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2016
1Lymphocytosis
01/2016
1Lymphadenopathy
01/2016
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/2010
1Pancreatic Neoplasms (Pancreatic Cancer)
03/2008
1Neoplasm Metastasis (Metastasis)
07/2007
1Carcinoma (Carcinomatosis)
07/2007
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/2004

Drug/Important Bio-Agent (IBA)

7idecabtagene vicleucelIBA
11/2023 - 01/2019
6Chimeric Antigen ReceptorsIBA
11/2023 - 01/2019
6Phosphotransferases (Kinase)IBA
01/2019 - 10/2013
6Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
01/2014 - 02/2004
5B-Cell Maturation AntigenIBA
11/2023 - 01/2019
43- (5- amino- 2- methyl- 4- oxoquinazolin- 3(4H)- yl)piperidine- 2,6- dioneIBA
02/2022 - 01/2019
4bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA
01/2021 - 01/2019
3CC-223IBA
02/2022 - 10/2015
3Mechanistic Target of Rapamycin Complex 2IBA
01/2019 - 10/2013
3Mechanistic Target of Rapamycin Complex 1IBA
01/2019 - 10/2013
3DNA (Deoxyribonucleic Acid)IBA
01/2019 - 10/2013
3IpilimumabIBA
01/2014 - 05/2012
3VaccinesIBA
05/2012 - 02/2004
2Biomarkers (Surrogate Marker)IBA
01/2021 - 02/2013
2TOR Serine-Threonine KinasesIBA
01/2019 - 10/2015
21- ethyl- 7- (2- methyl- 6- (1H- 1,2,4- triazol- 3- yl)pyridin- 3- yl)- 3,4- dihydropyrazino(2,3- b)pyrazin- 2(1H)- oneIBA
01/2019 - 01/2016
2MTOR InhibitorsIBA
01/2019 - 10/2015
26- (4- (1H- 1,2,4- triazol- 3- yl)phenyl)- 1- (2- (tetrahydro- 2H- pyran- 4- yl)ethyl)- 1H- imidazo(4,5- b)pyrazin- 2(3H)- oneIBA
04/2015 - 10/2013
1Adrenal Cortex Hormones (Corticosteroids)IBA
11/2023
1tocilizumab (atlizumab)FDA Link
11/2023
1Monoclonal AntibodiesIBA
03/2022
1Aspartate Aminotransferases (Aspartate Transaminase)IBA
03/2022
1CC-90002IBA
03/2022
1spebrutinibIBA
02/2022
1Rituximab (Mabthera)FDA Link
02/2022
1belantamab mafodotinIBA
10/2021
1Proteasome InhibitorsIBA
10/2021
1obinutuzumabIBA
09/2020
1AntibodiesIBA
09/2020
1Transaminases (Aminotransferases)IBA
01/2019
1Protein Kinases (Protein Kinase)IBA
01/2019
1Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
01/2019
1DNA-Activated Protein KinaseIBA
01/2019
1Eukaryotic Initiation Factor-4G (Eukaryotic Initiation Factor 4G)IBA
04/2015
1Cyclin D3IBA
04/2015
1Eukaryotic Initiation Factor-4EIBA
04/2015
1Eukaryotic Initiation Factor-4F (EIF4F)IBA
04/2015
1Sirolimus (Rapamycin)FDA Link
10/2013
1epidermal growth factor receptor VIIIIBA
10/2013
1CC214-2IBA
10/2013
1Adenosine Triphosphate (ATP)IBA
10/2013
1CTLA-4 AntigenIBA
05/2012
1Imatinib Mesylate (Gleevec)FDA Link
01/2010
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
03/2008
1Hormones (Hormone)IBA
07/2007
1Prostate-Specific Antigen (Semenogelase)IBA
07/2007
1Cytotoxins (Cytolysins)IBA
01/2007
1Cancer VaccinesIBA
02/2004

Therapy/Procedure

8Therapeutics
02/2022 - 12/2011
8Immunotherapy
01/2021 - 07/2007
4Drug Therapy (Chemotherapy)
09/2020 - 07/2007
3Castration
01/2019 - 05/2012